Shenyang Xingqi Pharmaceutical Co Ltd (300573) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenyang Xingqi Pharmaceutical Co Ltd (300573) has a cash flow conversion efficiency ratio of 0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥268.97 Million ≈ $39.36 Million USD) by net assets (CN¥1.86 Billion ≈ $271.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shenyang Xingqi Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Shenyang Xingqi Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Shenyang Xingqi Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shenyang Xingqi Pharmaceutical Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Shenyang Xingqi Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenyang Xingqi Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
-0.001x |
|
JiangXi Tianxin Pharm Co Ltd
SHG:603235
|
N/A |
|
Serena Energia S.A.
SA:SRNA3
|
-0.007x |
|
Guizhou Panjiang Refined Coal Co Ltd
SHG:600395
|
0.025x |
|
Bilia AB (publ)
ST:BILI-A
|
0.122x |
|
Bank Ina Perdana PT
JK:BINA
|
-0.047x |
|
Thai Union Group PCL
BK:TU
|
0.003x |
|
SPG Co. Ltd
KQ:058610
|
0.025x |
Annual Cash Flow Conversion Efficiency for Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Shenyang Xingqi Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.59 Billion ≈ $233.13 Million |
CN¥416.98 Million ≈ $61.02 Million |
0.262x | +39.28% |
| 2023-12-31 | CN¥1.69 Billion ≈ $247.29 Million |
CN¥317.57 Million ≈ $46.47 Million |
0.188x | +1.90% |
| 2022-12-31 | CN¥1.55 Billion ≈ $227.15 Million |
CN¥286.26 Million ≈ $41.89 Million |
0.184x | -19.23% |
| 2021-12-31 | CN¥1.34 Billion ≈ $196.74 Million |
CN¥306.96 Million ≈ $44.92 Million |
0.228x | +29.72% |
| 2020-12-31 | CN¥694.06 Million ≈ $101.56 Million |
CN¥122.16 Million ≈ $17.88 Million |
0.176x | +36.59% |
| 2019-12-31 | CN¥574.90 Million ≈ $84.13 Million |
CN¥74.08 Million ≈ $10.84 Million |
0.129x | +62.38% |
| 2018-12-31 | CN¥554.58 Million ≈ $81.15 Million |
CN¥44.01 Million ≈ $6.44 Million |
0.079x | +34.31% |
| 2017-12-31 | CN¥553.38 Million ≈ $80.98 Million |
CN¥32.70 Million ≈ $4.78 Million |
0.059x | +9.45% |
| 2016-12-31 | CN¥520.95 Million ≈ $76.23 Million |
CN¥28.12 Million ≈ $4.12 Million |
0.054x | -1.82% |
| 2015-12-31 | CN¥389.79 Million ≈ $57.04 Million |
CN¥21.43 Million ≈ $3.14 Million |
0.055x | +55.59% |
| 2014-12-31 | CN¥367.81 Million ≈ $53.82 Million |
CN¥13.00 Million ≈ $1.90 Million |
0.035x | +41.72% |
| 2013-12-31 | CN¥336.80 Million ≈ $49.28 Million |
CN¥8.40 Million ≈ $1.23 Million |
0.025x | -82.72% |
| 2012-12-31 | CN¥290.70 Million ≈ $42.54 Million |
CN¥41.96 Million ≈ $6.14 Million |
0.144x | +45.29% |
| 2011-12-31 | CN¥247.00 Million ≈ $36.14 Million |
CN¥24.54 Million ≈ $3.59 Million |
0.099x | -- |
About Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs… Read more